The 200Bn Method is the proprietary assessment and founder-readiness system behind The 200Bn Club. It was built to answer one question:
What if founders were assessed against evidence, behaviour and progress. Not polish, pattern-matching or proximity to power?
Venture’s default instrument is the gut: warm introductions, familiar patterns, “looks like a founder”. It works well for founders who fit the pattern. For everyone else, it can miss what matters. So we built the Method where those mistakes are most likely to happen, and tested whether it could identify strong founders and businesses without relying on those familiar signals. It could. Now the same rigour is used to assess every founder, at every stage and in every category.
The Method assesses each company, benchmarks it against successful startups in the same category, diagnoses the gaps blocking capital, prescribes a 90-day action plan matched to interactive Playbooks, and proves progress through the work founders produce.
Every founder completes a structured assessment adapted by stage, sector and business model - founder, company, market, product, traction or milestones, economics, risk and funding logic - with deck and financial model where relevant.
The engine benchmarks the company against successful startups and investor expectations in the same category. The Fundability Review and VC Investment Memo name what is strong, what is missing, what blocks capital, and what evidence would change the decision.
The gaps become a 90-day action plan, matched to interactive Playbooks. Not vague feedback: what to fix, why it matters, what evidence to produce - every action removes a specific investor objection.
Founders complete the workbooks and produce the evidence - a unit economics sheet, a regulatory pathway, a milestone map, a paid pilot, a retention curve. The output is reviewed and the gap is scored again.
Where the Method leads: relevant investor access for founders who prove readiness - and, as we build the 200Bn Fund, capital of our own.
A founder can spend weeks preparing an application, a deck or a pitch, only to receive a polite no with no useful diagnosis. That is not assessment. That is theatre.
“Your pitch needs work.”
“You say you have product-market fit, but your churn tells a different story. Here is what to prove next.”
“You are too early.”
“Your technical milestone is credible, but your regulatory path and capital plan are not yet investable. Here is the work that closes the gap.”
Every assessed founder leaves with a diagnosis and a clear plan to move closer to fundable.
Leave no founder behind.
The Method breaks founder readiness into measurable risk vectors, calibrated by stage, sector, business model and funding path - 25,610+ contextual anchors defining what strong, mid and weak evidence looks like in each category. A SaaS founder, a biotech founder and a hardware founder are not assessed in the same way. Different evidence. Same standard.
Each company is scored independently across six pillars.
The founder's edge, speed of learning, execution capacity, founder-market fit and team coverage.
Evidence that the market, customer, partner, user, patient, regulator or technical domain is responding.
The size, urgency and timing of the opportunity: why now, why this wedge, why this founder.
Product, technology, defensibility, IP, data, regulatory position, technical and execution risk.
Capital need, runway, unit economics, milestone financing, burn, value inflection and next-round logic.
Round structure, valuation sanity, dilution logic, capital stack and investability of the deal.
The point is not to average everything into a bland score. It is to isolate the signal, find the blockers and show what needs to move.
Investor Readiness Score, six-pillar breakdown, strongest signals, funding blockers, 90-day action plan and investor push questions. Not a report card - a roadmap.
A 14-section memo that reads like an investment committee note and ends where a real memo ends: Back. Lean In. Conditions. Pass. Uncomfortable, and useful.
A 13-section dossier covering founder snapshot, knowns and unknowns, risks, mentor matching and the next two weeks' priorities.
For companies in biotech, deeptech, medtech, climate, hardware and regulated markets, the next investable step is often a milestone, not revenue: a patent filed, a pilot signed, a regulatory pathway clarified, a technical risk retired. The Method treats these as evidence when they are the right evidence for the business. It does not ask every company to look like SaaS. It asks every company to prove the right thing next.
Each action in the 90-day plan is backed by a specific interactive Playbook with a workbook, worked examples and a concrete output. A founder with unknown CAC is not told to "improve metrics" - they are matched to the unit economics interactive Playbook. A founder with an unclear regulatory pathway is matched to the regulatory strategy interactive Playbook.
The point is not learning. The point is execution and proof.
Is there a sharp founder with a credible wedge, a serious market and evidence that the next risk can be retired?
Can this company turn the next tranche of capital into a meaningful increase in value?
Does the company have enough evidence, team depth and execution capacity to scale without the story breaking?
For the first time since I've started building the app, I got honest feedback on every aspect of my business instead of a polite rejection. The memo didn't just say 'not ready' - it showed me exactly what blocks funding and gave me a concrete roadmap to fix it.
The risk here isn't vision, it's proof. The review highlighted an evidence gap, not an existential flaw - which is exactly what I needed to see.
I am very grateful to you for this review. It would have been really hard - if not impossible - for me to obtain this level of insight into my business from another source.
We're one week in and I already can't believe how lucky I am that Pesto was selected for the Breakthrough Founders 2026 Cohort. ...with one of the hardest, most thorough and valuable application processes I've ever been through... Thank you to The 200Bn Club and Innovate UK for the opportunity - I can't think of better preparation for our seed round later this year.
The Method finds the spike, diagnoses the gaps, prescribes the work and proves whether founders can turn feedback into evidence. That is how founders become investable at the highest standard, before they become inevitable.
